For more detailed information about the cookies we use, see our Cookies page.
Essential Cookies enable core functionality such as security, network management, and accessibility. These cookies are necessary for the performance of the service and may not be removed.
Non-Essential Cookies are preference, marketing, and functional cookies that help the application perform to its full extent, advertising related to the IdeaScale marketing website, and ensure the application functions properly. Preferences cookies personalize your experience while accessing IdeaScale by remembering your preferences, such as preferred language and region of origin. Analytics cookies collect anonymized information about how you use the IdeaScale services, such as the IdeaScale pages you visit most frequently and the error messages you encounter. These cookies only analyze your movement within IdeaScale and are used to improve the functioning of IdeaScale services. Marketing cookies advertise IdeaScale services to you elsewhere on the Internet. These cookies enable the delivery of interest-based ads that may be relevant to you as a result of your activities on IdeaScale and provide IdeaScale with information (such as where you saw the ad) to help analyze the impact of its advertising campaigns. IdeaScale also includes links to social networks and third-party sites (for example, Facebook and LinkedIn), which may then use information about your visit to target advertising to you on their websites.
How can the effectiveness of existing curative therapies be improved for allogeneic hematopoietic stem cell transplantation?
Is this idea a Compelling Question (CQ) or Critical Challenge (CC)?
Compelling Question (CQ)
Details on the impact of addressing this CQ or CC
Much remains to be understood about immunotherapies in order to facilitate their broad use in the treatment of hematologic disorders. While studies to date have demonstrated significant potential applications, longer-term studies are necessary to further improve the profile of these therapies, including enhancing their overall efficacy while reducing associated toxicities. The efficacy of existing curative therapies can be enhanced by evaluating the mechanisms involved in producing cytokine release syndrome; a condition which has been observed in several patients receiving this therapy. Furthermore, a careful grading scheme to predict toxicity so as to guide the development of preventive and therapeutic strategies is also required. Target identification is another important issue to advance the field. While targeting CD19 appears to be promising, it results in loss of B-cell immunity and requires prolonged immunoglobulin replacement therapies and/or allo-transplantation and new immunologic targets need to be identified in both B cell and T cell malignancies as was as acute and chronic myeloid leukemias. Minimizing the off-tumor target-mediated toxicity of both CAR T-cell and checkpoint blockade therapies would help optimize their utility.
Name of idea submitter and other team members who worked on this idea
Alice Kuaban on behalf of the American Society of Hematology (ASH)